Induction Period: Participants >=30 kg, Vedolizumab 300 mg<br>Vedolizumab 300 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with CD having Baseline weight of >=30 kg will be included in this arm group<br><br>Induction Period: Participants >15 to <30 kg, Vedolizumab 200 mg<br>Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with CD having Baseline weight of >15 to <30 kg will be included in this arm group.<br><br>Induction Period: Participants 10 to 15 kg, Vedolizumab 150 mg<br>Vedolizumab 150 mg, IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period. Participants with CD having Baseline weight of 10 to 15 kg will be included in this armgroup.<br><br>Maintenance Period: Participants >=30 kg, Vedolizumab 300 mg<br>Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >=30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.<br><br>Maintenance Period: Participants >=30 kg, Vedolizumab 150 mg<br>Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >=30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.<br><br>Maintenance Period: Participants >15 to <30 kg, Vedolizumab 200 mg<br>Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of >15 to <30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.<br><br>Maintenance Period: Participants >15 to <30 kg, Vedolizumab 100 mg<br>Vedolizumab 100 mg, IV infusion, Q8W

( DrugBank: - )

96. Crohn disease